BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25784716)

  • 1. Endophilin A2 Promotes TNBC Cell Invasion and Tumor Metastasis.
    Baldassarre T; Watt K; Truesdell P; Meens J; Schneider MM; Sengupta SK; Craig AW
    Mol Cancer Res; 2015 Jun; 13(6):1044-55. PubMed ID: 25784716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
    Baldassarre T; Truesdell P; Craig AW
    Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
    Cerqueira OL; Truesdell P; Baldassarre T; Vilella-Arias SA; Watt K; Meens J; Chander H; Osório CA; Soares FA; Reis EM; Craig AW
    Oncotarget; 2015 Apr; 6(11):9397-408. PubMed ID: 25823823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
    Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
    Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
    Das SG; Romagnoli M; Mineva ND; Barillé-Nion S; Jézéquel P; Campone M; Sonenshein GE
    Breast Cancer Res; 2016 Apr; 18(1):40. PubMed ID: 27039296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer.
    Chen HA; Chang YW; Tseng CF; Chiu CF; Hong CC; Wang W; Wang MY; Hsiao M; Ma JT; Chen CH; Jiang SS; Wu CH; Hung MC; Huang MT; Su JL
    Ann Surg Oncol; 2015 Mar; 22(3):889-98. PubMed ID: 25212833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.
    Kannan A; Philley JV; Hertweck KL; Ndetan H; Singh KP; Sivakumar S; Wells RB; Vadlamudi RK; Dasgupta S
    Sci Rep; 2019 Aug; 9(1):11632. PubMed ID: 31406142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF13 promotes metastasis of triple-negative breast cancer.
    Johnstone CN; Pattison AD; Harrison PF; Powell DR; Lock P; Ernst M; Anderson RL; Beilharz TH
    Int J Cancer; 2020 Jul; 147(1):230-243. PubMed ID: 31957002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
    Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
    J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation-induced lung metastasis development is MT1-MMP-dependent in a triple-negative breast cancer mouse model.
    Bouchard G; Therriault H; Geha S; Bujold R; Saucier C; Paquette B
    Br J Cancer; 2017 Feb; 116(4):479-488. PubMed ID: 28103615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annexin A2 depletion delays EGFR endocytic trafficking via cofilin activation and enhances EGFR signaling and metastasis formation.
    de Graauw M; Cao L; Winkel L; van Miltenburg MH; le Dévédec SE; Klop M; Yan K; Pont C; Rogkoti VM; Tijsma A; Chaudhuri A; Lalai R; Price L; Verbeek F; van de Water B
    Oncogene; 2014 May; 33(20):2610-9. PubMed ID: 23792445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs).
    Orr K; Buckley NE; Haddock P; James C; Parent JL; McQuaid S; Mullan PB
    Oncotarget; 2016 Aug; 7(34):55458-55472. PubMed ID: 27487152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer.
    Huang SP; Liu PY; Kuo CJ; Chen CL; Lee WJ; Tsai YH; Lin YF
    J Hematol Oncol; 2017 Jun; 10(1):114. PubMed ID: 28576130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer cell-associated MT1-MMP promotes blood vessel invasion and distant metastasis in triple-negative mammary tumors.
    Perentes JY; Kirkpatrick ND; Nagano S; Smith EY; Shaver CM; Sgroi D; Garkavtsev I; Munn LL; Jain RK; Boucher Y
    Cancer Res; 2011 Jul; 71(13):4527-38. PubMed ID: 21571860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis.
    Ahn J; Truesdell P; Meens J; Kadish C; Yang X; Boag AH; Craig AW
    Mol Cancer Res; 2013 Aug; 11(8):952-63. PubMed ID: 23699534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.
    Powell CA; Nasser MW; Zhao H; Wochna JC; Zhang X; Shapiro C; Shilo K; Ganju RK
    Oncotarget; 2015 Mar; 6(8):6373-85. PubMed ID: 25779666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FAK-mediated src phosphorylation of endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation.
    Wu X; Gan B; Yoo Y; Guan JL
    Dev Cell; 2005 Aug; 9(2):185-96. PubMed ID: 16054026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype.
    He Q; Jing H; Liaw L; Gower L; Vary C; Hua S; Yang X
    Sci Rep; 2016 Mar; 6():23216. PubMed ID: 26976794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.